Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Göhring G[au]:

Search results

Items: 1 to 50 of 185

1.

Generation of an induced pluripotent stem cell line (MHHi018-A) from a patient with Cystic Fibrosis carrying p.Asn1303Lys (N1303K) mutation.

Merkert S, Schubert M, Haase A, Janssens HM, Scholte B, Lachmann N, Göhring G, Martin U.

Stem Cell Res. 2020 Mar 25;44:101744. doi: 10.1016/j.scr.2020.101744. [Epub ahead of print]

2.

Implementation of RNA sequencing and array CGH in the diagnostic workflow of the AIEOP-BFM ALL 2017 trial on acute lymphoblastic leukemia.

Schieck M, Lentes J, Thomay K, Hofmann W, Behrens YL, Hagedorn M, Ebersold J, Davenport CF, Fazio G, Möricke A, Buchmann S, Alten J, Cario G, Schrappe M, Bergmann AK, Stanulla M, Steinemann D, Schlegelberger B, Cazzaniga G, Göhring G.

Ann Hematol. 2020 Apr;99(4):809-818. doi: 10.1007/s00277-020-03953-3. Epub 2020 Feb 20.

3.

Generation of three induced pluripotent stem cell lines (MHHi012-A, MHHi013-A, MHHi014-A) from a family with Loeys-Dietz syndrome carrying a heterozygous p.M253I (c.759G>A) mutation in the TGFBR1 gene.

Pongpamorn P, Dahlmann J, Haase A, Ebeling CT, Merkert S, Göhring G, Lachmann N, Martens A, Haverich A, Martin U, Olmer R.

Stem Cell Res. 2020 Mar;43:101707. doi: 10.1016/j.scr.2020.101707. Epub 2020 Feb 4.

4.

Human STAT1 gain-of-function iPSC line from a patient suffering from chronic mucocutaneous candidiasis.

Haake K, Wüstefeld T, Merkert S, Lüttge D, Göhring G, Auber B, Baumann U, Lachmann N.

Stem Cell Res. 2020 Mar;43:101713. doi: 10.1016/j.scr.2020.101713. Epub 2020 Jan 17.

5.

Induced pluripotent stem cell line (PEIi003-A) derived from an apparently healthy male individual.

Fuchs NV, Schieck M, Neuenkirch M, Tondera C, Schmitz H, Steinemann D, Göhring G, König R.

Stem Cell Res. 2020 Jan;42:101679. doi: 10.1016/j.scr.2019.101679. Epub 2019 Dec 4.

6.

Generation of a NKX2.1 - p63 double transgenic knock-in reporter cell line from human induced pluripotent stem cells (MHHi006-A-4).

Drick N, Sahabian A, Pongpamorn P, Merkert S, Göhring G, Welte T, Martin U, Olmer R.

Stem Cell Res. 2020 Jan;42:101659. doi: 10.1016/j.scr.2019.101659. Epub 2019 Nov 19.

7.

Induced pluripotent stem cells (iPSCs) derived from a renpenning syndrome patient with c.459_462delAGAG mutation in PQBP1 (PEIi001-A).

Fuchs NV, Schieck M, Neuenkirch M, Tondera C, Schmitz H, des Portes V, Germanaud D, Steinemann D, Göhring G, König R.

Stem Cell Res. 2019 Dec;41:101592. doi: 10.1016/j.scr.2019.101592. Epub 2019 Oct 15.

8.

FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.

Shahswar R, Beutel G, Klement P, Rehberg A, Gabdoulline R, Koenecke C, Markel D, Eggers H, Eder M, Stadler M, Hambach L, Ehrlich S, Göhring G, Schlegelberger B, Dammann E, Reuter M, Wichmann M, Neziri B, Ganser A, Thol F, Heuser M.

Br J Haematol. 2020 Feb;188(3):e11-e15. doi: 10.1111/bjh.16268. Epub 2019 Nov 4. No abstract available.

PMID:
31681986
9.

Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols.

Cario G, Leoni V, Conter V, Attarbaschi A, Zaliova M, Sramkova L, Cazzaniga G, Fazio G, Sutton R, Elitzur S, Izraeli S, Lauten M, Locatelli F, Basso G, Buldini B, Bergmann AK, Lentes J, Steinemann D, Göhring G, Schlegelberger B, Haas OA, Schewe D, Buchmann S, Moericke A, White D, Revesz T, Stanulla M, Mann G, Bodmer N, Arad-Cohen N, Zuna J, Valsecchi MG, Zimmermann M, Schrappe M, Biondi A.

Haematologica. 2019 Oct 10. pii: haematol.2019.231720. doi: 10.3324/haematol.2019.231720. [Epub ahead of print]

10.

Generation of a CFTR knock-in reporter cell line (MHHi006-A-1) from a human induced pluripotent stem cell line.

Engels L, Olmer R, de la Roche J, Göhring G, Ulrich S, Haller R, Martin U, Merkert S.

Stem Cell Res. 2019 Oct;40:101542. doi: 10.1016/j.scr.2019.101542. Epub 2019 Aug 20.

11.

Generation of a NKX2.1 knock-in reporter cell line from human induced pluripotent stem cells (MHHi006-A-2).

Olmer R, Dahlmann J, Merkert S, Baus S, Göhring G, Martin U.

Stem Cell Res. 2019 Aug;39:101492. doi: 10.1016/j.scr.2019.101492. Epub 2019 Jun 28.

12.

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.

Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rücker FG, Lux S, Blätte TJ, Skambraks S, Krönke J, Heidel FH, Schnöder TM, Corbacioglu A, Gaidzik VI, Paschka P, Teleanu V, Göhring G, Thol F, Heuser M, Ganser A, Weber D, Sträng E, Kestler HA, Döhner H, Bullinger L, Döhner K.

Nat Commun. 2019 May 2;10(1):2031. doi: 10.1038/s41467-019-09745-2.

13.

Comprehensive analysis of isolated der(1;7)(q10;p10) in a large international homogenous cohort of patients with myelodysplastic syndromes.

Ganster C, Müller-Thomas C, Haferlach C, Strupp C, Ogata K, Germing U, Hildebrandt B, Mallo M, Lübbert M, Müller C, Solé F, Götze KS, Vandenberghe P, Göhring G, Steinmetz T, Kröger N, Platzbecker U, Söling U, Raynaud S, Shirneshan K, Schanz J, Haase D.

Genes Chromosomes Cancer. 2019 Oct;58(10):689-697. doi: 10.1002/gcc.22760. Epub 2019 Apr 30.

PMID:
30994215
14.

Generation of an induced pluripotent stem cell (iPSC) line, DHMCi005-A, from a patient with CALFAN syndrome due to mutations in SCYL1.

Lenz D, Staufner C, Wächter S, Hagedorn M, Ebersold J, Göhring G, Kölker S, Hoffmann GF, Jung-Klawitter S.

Stem Cell Res. 2019 May;37:101428. doi: 10.1016/j.scr.2019.101428. Epub 2019 Mar 22.

15.

Generation of 2 iPSC clones from a patient with DNAJC12 deficiency: DHMCi003-A and DHMCi003-B.

Jung-Klawitter S, Wächter S, Hagedorn M, Ebersold J, Göhring G, Opladen T.

Stem Cell Res. 2019 Apr;36:101402. doi: 10.1016/j.scr.2019.101402. Epub 2019 Mar 8.

16.

Generation of an iPSC line from a patient with infantile liver failure syndrome 2 due to mutations in NBAS: DHMCi004-A.

Lenz D, Staufner C, Wächter S, Hagedorn M, Ebersold J, Göhring G, Kölker S, Hoffmann GF, Jung-Klawitter S.

Stem Cell Res. 2019 Mar;35:101398. doi: 10.1016/j.scr.2019.101398. Epub 2019 Feb 11.

17.

GMP-compatible manufacturing of three iPS cell lines from human peripheral blood.

Haase A, Glienke W, Engels L, Göhring G, Esser R, Arseniev L, Martin U.

Stem Cell Res. 2019 Mar;35:101394. doi: 10.1016/j.scr.2019.101394. Epub 2019 Feb 11.

18.

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Schlenk RF, Weber D, Herr W, Wulf G, Salih HR, Derigs HG, Kuendgen A, Ringhoffer M, Hertenstein B, Martens UM, Grießhammer M, Bernhard H, Krauter J, Girschikofsky M, Wolf D, Lange E, Westermann J, Koller E, Kremers S, Wattad M, Heuser M, Thol F, Göhring G, Haase D, Teleanu V, Gaidzik V, Benner A, Döhner K, Ganser A, Paschka P, Döhner H.

Leukemia. 2019 Aug;33(8):1923-1933. doi: 10.1038/s41375-019-0395-y. Epub 2019 Feb 6.

19.

Jumping translocations: Short telomeres or pathogenic TP53 variants as underlying mechanism in acute myeloid leukemia and myelodysplastic syndrome?

Behrens YL, Thomay K, Hagedorn M, Ebersold J, Schmidt G, Lentes J, Davenport C, Schlegelberger B, Göhring G.

Genes Chromosomes Cancer. 2019 Mar;58(3):139-148. doi: 10.1002/gcc.22665. Epub 2019 Jan 7.

PMID:
30614587
20.

Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion.

Feurstein S, Thomay K, Hofmann W, Buesche G, Kreipe H, Thol F, Heuser M, Ganser A, Schlegelberger B, Göhring G.

Int J Mol Sci. 2018 Oct 21;19(10). pii: E3269. doi: 10.3390/ijms19103269.

21.

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).

Sekeres MA, Swern AS, Giagounidis A, List AF, Selleslag D, Mittelman M, Schlegelberger B, Göhring G, Li JS, Sugrue MM, Fenaux P.

Blood Cancer J. 2018 Sep 21;8(10):90. doi: 10.1038/s41408-018-0126-z. No abstract available.

22.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik VI, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk RF, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M.

Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6.

PMID:
30190321
23.

iPSC-Derived Macrophages Effectively Treat Pulmonary Alveolar Proteinosis in Csf2rb-Deficient Mice.

Mucci A, Lopez-Rodriguez E, Hetzel M, Liu S, Suzuki T, Happle C, Ackermann M, Kempf H, Hillje R, Kunkiel J, Janosz E, Brennig S, Glage S, Bankstahl JP, Dettmer S, Rodt T, Gohring G, Trapnell B, Hansen G, Trapnell C, Knudsen L, Lachmann N, Moritz T.

Stem Cell Reports. 2018 Sep 11;11(3):696-710. doi: 10.1016/j.stemcr.2018.07.006. Epub 2018 Aug 9.

24.

Effect of TP53 contact and conformational mutations on cell survival and erythropoiesis of human hematopoietic stem cells in a long term culture model.

Salari A, Thomay K, Lentes J, Ebersold J, Hagedorn M, Skawran B, Davenport C, Schambach A, Schlegelberger B, Göhring G.

Oncotarget. 2018 Jul 6;9(52):29869-29876. doi: 10.18632/oncotarget.25581. eCollection 2018 Jul 6.

25.

Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.

Suttorp M, Schulze P, Glauche I, Göhring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Groß-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C.

Leukemia. 2018 Jul;32(7):1657-1669. doi: 10.1038/s41375-018-0179-9. Epub 2018 Jun 20.

PMID:
29925908
26.

Generation of a human CDX2 knock-in reporter iPSC line (MHHi007-A-1) to model human trophoblast differentiation.

Malysheva SV, Wunderlich S, Haase A, Göhring G, Martin U, Merkert S.

Stem Cell Res. 2018 Jul;30:117-121. doi: 10.1016/j.scr.2018.05.015. Epub 2018 May 19.

27.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.

Leukemia. 2018 Jul;32(7):1621-1630. doi: 10.1038/s41375-018-0129-6. Epub 2018 Apr 17.

PMID:
29720733
28.

Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation.

Sellmann L, Rabe K, Bünting I, Dammann E, Göhring G, Ganser A, Stadler M, Weissinger EM, Hambach L.

Bone Marrow Transplant. 2018 Nov;53(11):1457-1465. doi: 10.1038/s41409-018-0176-7. Epub 2018 May 2.

PMID:
29720704
29.

Differentiation of Human Pluripotent Stem Cells into Functional Endothelial Cells in Scalable Suspension Culture.

Olmer R, Engels L, Usman A, Menke S, Malik MNH, Pessler F, Göhring G, Bornhorst D, Bolten S, Abdelilah-Seyfried S, Scheper T, Kempf H, Zweigerdt R, Martin U.

Stem Cell Reports. 2018 May 8;10(5):1657-1672. doi: 10.1016/j.stemcr.2018.03.017. Epub 2018 Apr 19.

30.

Pulmonary Transplantation of Human Induced Pluripotent Stem Cell-derived Macrophages Ameliorates Pulmonary Alveolar Proteinosis.

Happle C, Lachmann N, Ackermann M, Mirenska A, Göhring G, Thomay K, Mucci A, Hetzel M, Glomb T, Suzuki T, Chalk C, Glage S, Dittrich-Breiholz O, Trapnell B, Moritz T, Hansen G.

Am J Respir Crit Care Med. 2018 Aug 1;198(3):350-360. doi: 10.1164/rccm.201708-1562OC.

31.

Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy.

Thomay K, Behrens YL, Lentes J, Wittner N, Wittig V, Rothe D, Steinemann D, Schlegelberger B, Göhring G.

Leuk Lymphoma. 2018 Oct;59(10):2478-2481. doi: 10.1080/10428194.2018.1427861. Epub 2018 Jan 31. No abstract available.

PMID:
29384408
32.

Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.

Naumann N, Jawhar M, Schwaab J, Kluger S, Lübke J, Metzgeroth G, Popp HD, Khaled N, Horny HP, Sotlar K, Valent P, Haferlach C, Göhring G, Schlegelberger B, Meggendorfer M, Hofmann WK, Cross NCP, Reiter A, Fabarius A.

Genes Chromosomes Cancer. 2018 May;57(5):252-259. doi: 10.1002/gcc.22526. Epub 2018 Feb 19.

PMID:
29341334
33.

Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells.

Pittermann E, Lachmann N, MacLean G, Emmrich S, Ackermann M, Göhring G, Schlegelberger B, Welte K, Schambach A, Heckl D, Orkin SH, Cantz T, Klusmann JH.

Blood Adv. 2017 Jun 2;1(14):903-914. doi: 10.1182/bloodadvances.2016003798. eCollection 2017 Jun 13.

34.

Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).

Schrappe M, Bleckmann K, Zimmermann M, Biondi A, Möricke A, Locatelli F, Cario G, Rizzari C, Attarbaschi A, Valsecchi MG, Bartram CR, Barisone E, Niggli F, Niemeyer C, Testi AM, Mann G, Ziino O, Schäfer B, Panzer-Grümayer R, Beier R, Parasole R, Göhring G, Ludwig WD, Casale F, Schlegel PG, Basso G, Conter V.

J Clin Oncol. 2018 Jan 20;36(3):244-253. doi: 10.1200/JCO.2017.74.4946. Epub 2017 Nov 17.

35.

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih HR, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs HG, Horst HA, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik VI, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group (AMLSG).

Ann Hematol. 2017 Dec;96(12):1993-2003. doi: 10.1007/s00277-017-3150-3. Epub 2017 Oct 31.

36.

Corrigendum: Clinical and Molecular Heterogeneity of RTEL1 Deficiency.

Speckmann C, Sahoo SS, Rizzi M, Hirabayashi S, Karow A, Serwas NK, Hoemberg M, Damatova N, Schindler D, Vannier JB, Boulton SJ, Pannicke U, Göhring G, Thomay K, Verdu-Amoros JJ, Hauch H, Woessmann W, Escherich G, Laack E, Rindle L, Seidl M, Rensing-Ehl A, Lausch E, Jandrasits C, Strahm B, Schwarz K, Ehl SR, Niemeyer C, Boztug K, Wlodarski MW.

Front Immunol. 2017 Oct 2;8:1250. doi: 10.3389/fimmu.2017.01250. eCollection 2017.

37.

Generation of a gene-corrected isogenic control iPSC line from cystic fibrosis patient-specific iPSCs homozygous for p.Phe508del mutation mediated by TALENs and ssODN.

Merkert S, Bednarski C, Göhring G, Cathomen T, Martin U.

Stem Cell Res. 2017 Aug;23:95-97. doi: 10.1016/j.scr.2017.07.010. Epub 2017 Jul 11.

38.

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.

Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kröger N.

Bone Marrow Transplant. 2017 Nov;52(11):1519-1525. doi: 10.1038/bmt.2017.171. Epub 2017 Sep 11.

39.

The MLL recombinome of acute leukemias in 2017.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R.

Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.

40.

Telomere shortening, TP53 mutations and deletions in chronic lymphocytic leukemia result in increased chromosomal instability and breakpoint clustering in heterochromatic regions.

Thomay K, Fedder C, Hofmann W, Kreipe H, Stadler M, Titgemeyer J, Zander I, Schlegelberger B, Göhring G.

Ann Hematol. 2017 Sep;96(9):1493-1500. doi: 10.1007/s00277-017-3055-1. Epub 2017 Jul 9.

PMID:
28691153
41.

Generation of non-transgenic iPS cells from human cord blood CD34+ cells under animal component-free conditions.

Haase A, Göhring G, Martin U.

Stem Cell Res. 2017 May;21:71-73. doi: 10.1016/j.scr.2017.03.022. Epub 2017 Mar 31.

42.

Characterization of High-Avidity Cytomegalovirus-Specific T Cells with Differential Tetramer Binding Coappearing after Allogeneic Stem Cell Transplantation.

Ogonek J, Verma K, Schultze-Florey C, Varanasi P, Luther S, Schweier P, Kühnau W, Göhring G, Dammann E, Stadler M, Ganser A, Koehl U, Koenecke C, Weissinger EM, Hambach L.

J Immunol. 2017 Jul 15;199(2):792-805. doi: 10.4049/jimmunol.1601992. Epub 2017 Jun 19.

43.

Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation.

Heuser M, Gabdoulline R, Löffeld P, Dobbernack V, Kreimeyer H, Pankratz M, Flintrop M, Liebich A, Klesse S, Panagiota V, Stadler M, Wichmann M, Shahswar R, Platzbecker U, Thiede C, Schroeder T, Kobbe G, Geffers R, Schlegelberger B, Göhring G, Kreipe HH, Germing U, Ganser A, Kröger N, Koenecke C, Thol F.

Ann Hematol. 2017 Aug;96(8):1361-1372. doi: 10.1007/s00277-017-3027-5. Epub 2017 Jun 13.

PMID:
28612220
44.

Comparison of different methods for telomere length measurement in whole blood and blood cell subsets: Recommendations for telomere length measurement in hematological diseases.

Behrens YL, Thomay K, Hagedorn M, Ebersold J, Henrich L, Nustede R, Schlegelberger B, Göhring G.

Genes Chromosomes Cancer. 2017 Sep;56(9):700-708. doi: 10.1002/gcc.22475. Epub 2017 Jul 3.

PMID:
28593741
45.

CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo.

Reimer J, Knöß S, Labuhn M, Charpentier EM, Göhring G, Schlegelberger B, Klusmann JH, Heckl D.

Haematologica. 2017 Sep;102(9):1558-1566. doi: 10.3324/haematol.2017.164046. Epub 2017 Jun 1.

46.

Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.

Jaramillo S, Benner A, Krauter J, Martin H, Kindler T, Bentz M, Salih HR, Held G, Köhne CH, Götze K, Lübbert M, Kündgen A, Brossart P, Wattad M, Salwender H, Hertenstein B, Nachbaur D, Wulf G, Horst HA, Kirchen H, Fiedler W, Raghavachar A, Russ G, Kremers S, Koller E, Runde V, Heil G, Weber D, Göhring G, Döhner K, Ganser A, Döhner H, Schlenk RF.

Blood Cancer J. 2017 May 26;7(5):e564. doi: 10.1038/bcj.2017.45.

47.

Clinical and Molecular Heterogeneity of RTEL1 Deficiency.

Speckmann C, Sahoo SS, Rizzi M, Hirabayashi S, Karow A, Serwas NK, Hoemberg M, Damatova N, Schindler D, Vannier JB, Boulton SJ, Pannicke U, Göhring G, Thomay K, Verdu-Amoros JJ, Hauch H, Woessmann W, Escherich G, Laack E, Rindle L, Seidl M, Rensing-Ehl A, Lausch E, Jandrasits C, Strahm B, Schwarz K, Ehl SR, Niemeyer C, Boztug K, Wlodarski MW.

Front Immunol. 2017 May 1;8:449. doi: 10.3389/fimmu.2017.00449. eCollection 2017. Erratum in: Front Immunol. 2017 Oct 02;8:1250.

48.

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.

Rasche M, von Neuhoff C, Dworzak M, Bourquin JP, Bradtke J, Göhring G, Escherich G, Fleischhack G, Graf N, Gruhn B, Haas OA, Klingebiel T, Kremens B, Lehrnbecher T, von Stackelberg A, Tchinda J, Zemanova Z, Thiede C, von Neuhoff N, Zimmermann M, Creutzig U, Reinhardt D.

Leukemia. 2017 Dec;31(12):2807-2814. doi: 10.1038/leu.2017.121. Epub 2017 Apr 25.

49.

Generation of an iPSC line from a patient with GTP cyclohydrolase 1 (GCH1) deficiency: HDMC0061i-GCH1.

Jung-Klawitter S, Ebersold J, Göhring G, Blau N, Opladen T.

Stem Cell Res. 2017 Apr;20:38-41. doi: 10.1016/j.scr.2017.02.010. Epub 2017 Feb 24.

50.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation.

Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz MM, Shahswar R, Ayuk F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe HH, Ganser A, Stocking C, Fehse B, Thol F, Heuser M.

Biol Blood Marrow Transplant. 2017 Jul;23(7):1095-1101. doi: 10.1016/j.bbmt.2017.03.034. Epub 2017 Apr 4.

Supplemental Content

Loading ...
Support Center